Meeting of the Office of Justice Programs' Science Advisory Board, 57177 [2013-22628]
Download as PDF
<![CDATA[
Federal Register / Vol. 78, No. 180 / Tuesday, September 17, 2013 / Notices
Drug
Schedule
tkelley on DSK3SPTVN1PROD with NOTICES
Dimethyltryptamine (7435) ...........
Psilocybin (7437) ..........................
Psilocyn (7438) .............................
5-Methoxy-N,Ndiisopropyltryptamine (7439).
N-Benzylpiperazine (7493) ...........
MDPV (7535) ................................
Methylone (7540) .........................
Desomorphine (9055) ...................
Etorphine (except HCl) (9056) .....
Heroin (9200) ...............................
Morphine-N-oxide (9307) .............
Normorphine (9313) .....................
Pholcodine (9314) ........................
Dextromoramide (9613) ...............
Dipipanone (9622) ........................
Racemoramide (9645) ..................
Trimeperidine (9646) ....................
1-Methyl-4-phenyl-4propionoxypiperidine (9661).
Tilidine (9750) ...............................
Amphetamine (1100) ....................
Methamphetamine (1105) ............
Methylphenidate (1724) ................
Amobarbital (2125) .......................
Pentobarbital (2270) .....................
Secobarbital (2315) ......................
Phencyclidine (7471) ....................
Phenylacetone (8501) ..................
Cocaine (9041) .............................
Codeine (9050) .............................
Dihydrocodeine (9120) .................
Oxycodone (9143) ........................
Hydromorphone (9150) ................
Ecgonine (9180) ...........................
Ethylmorphine (9190) ...................
Meperidine (9230) ........................
Methadone (9250) ........................
Dextropropoxyphene, bulk (nondosage forms) (9273).
Morphine (9300) ...........................
Oripavine (9330) ...........................
Thebaine (9333) ...........................
Levo-alphacetylmethadol (9648) ..
Oxymorphone (9652) ...................
Poppy Straw Concentrate (9670)
Alfentanil (9737) ...........................
Sufentanil (9740) ..........................
Fentanyl (9801) ............................
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
I
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
Dated: September 9, 2013.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
II
II
II
II
II
II
II
II
II
[FR Doc. 2013–22536 Filed 9–16–13; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJP) Docket No. 1631]
The company plans to import small
quantities of the listed controlled
substances for the manufacture of
analytical reference standards.
In reference to drug codes 7360 and
7370, the company plans to import a
synthetic cannabidiol and a synthetic
Tetrahydrocannabinol. No other activity
for this drug code is authorized for this
registration.
Comments and requests for hearing on
applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
Any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedules I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act 21 U.S.C. 952
(a)(2)(B) may, in the circumstances set
VerDate Mar<15>2010
17:05 Sep 16, 2013
Jkt 229001
forth in 21 U.S.C. 958(i), file comments
or objections to the issuance of the
proposed registration and may, at the
same time, file a written request for a
hearing on such application pursuant to
21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than October 17, 2013.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedules
I or II are, and will continue to be,
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Meeting of the Office of Justice
Programs’ Science Advisory Board
Office of Justice Programs
(OJP), Justice.
ACTION: Notice of meeting.
AGENCY:
This notice announces a
forthcoming meeting of OJP’s Science
Advisory Board (‘‘Board’’). The Board is
chartered to provide OJP, a component
of the Department of Justice, with
valuable advice in the areas of science
and statistics for the purpose of
enhancing the overall impact and
performance of its programs and
activities in criminal and juvenile
justice. To this end, the Board has
designated six (6) subcommittees:
National Institute of Justice (NIJ);
Bureau of Justice Statistics (BJS); Office
of Juvenile Justice and Delinquency
SUMMARY:
PO 00000
Frm 00051
Fmt 4703
Sfmt 9990
57177
Prevention (OJJDP); Bureau of Justice
Assistance; Quality and Protection of
Science; and Evidence Translation/
Integration.
The meeting will take place on
Friday, October 4, 2013, from 8:30 a.m.
to 4:00 p.m., ET, with a break for lunch
at approximately noon.
DATES:
The meeting will take place
in the Main Conference Room on the
third floor of the Office of Justice
Programs, 810 7th Street, Northwest,
Washington, DC 20531.
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
Phelan Wyrick, Designated Federal
Officer (‘‘DFO’’), Office of the Assistant
Attorney General, Office of Justice
Programs, 810 7th Street Northwest,
Washington, DC 20531; Phone: (202)
353–9254 [Note: this is not a toll-free
number]; Email: phelan.wyric@
usdoj.gov.
This
meeting is being convened to brief the
OJP Assistant Attorney General and the
Board members on the progress of the
subcommittees, discuss any
recommendations they may have for
consideration by the full Board, and
brief the Board on various OJP-related
projects and activities. The final agenda
is subject to adjustment, but it is
anticipated that there will be a morning
session and an afternoon session, with
a break for lunch. These sessions will
likely include briefings of the
subcommittees’ activities and
discussion of future Board actions and
priorities.
This meeting is open to the public.
Members of the public who wish to
attend this meeting must register with
Phelan Wyrick at the above address at
least seven (7) days in advance of the
meeting. Registrations will be accepted
on a space available basis. Access to the
meeting will not be allowed without
registration. Persons interested in
communicating with the Board should
submit their written comments to the
DFO, as the time available will not
allow the public to directly address the
Board at the meeting. Anyone requiring
special accommodations should notify
Mr. Wyrick at least seven (7) days in
advance of the meeting.
SUPPLEMENTARY INFORMATION:
Phelan Wyrick,
Science Policy Advisor and Science Advisory
Board DFO, Office of the Assistant Attorney
General, Office of Justice Programs.
[FR Doc. 2013–22628 Filed 9–16–13; 8:45 am]
BILLING CODE 4410–18–P
E:\FR\FM\17SEN1.SGM
17SEN1
]]>Agencies
[Federal Register Volume 78, Number 180 (Tuesday, September 17, 2013)]
[Notices]
[Page 57177]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2013-22628]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Office of Justice Programs
[OJP (OJP) Docket No. 1631]
Meeting of the Office of Justice Programs' Science Advisory Board
AGENCY: Office of Justice Programs (OJP), Justice.
ACTION: Notice of meeting.
-----------------------------------------------------------------------
SUMMARY: This notice announces a forthcoming meeting of OJP's Science
Advisory Board (``Board''). The Board is chartered to provide OJP, a
component of the Department of Justice, with valuable advice in the
areas of science and statistics for the purpose of enhancing the
overall impact and performance of its programs and activities in
criminal and juvenile justice. To this end, the Board has designated
six (6) subcommittees: National Institute of Justice (NIJ); Bureau of
Justice Statistics (BJS); Office of Juvenile Justice and Delinquency
Prevention (OJJDP); Bureau of Justice Assistance; Quality and
Protection of Science; and Evidence Translation/Integration.
DATES: The meeting will take place on Friday, October 4, 2013, from
8:30 a.m. to 4:00 p.m., ET, with a break for lunch at approximately
noon.
ADDRESSES: The meeting will take place in the Main Conference Room on
the third floor of the Office of Justice Programs, 810 7th Street,
Northwest, Washington, DC 20531.
FOR FURTHER INFORMATION CONTACT: Phelan Wyrick, Designated Federal
Officer (``DFO''), Office of the Assistant Attorney General, Office of
Justice Programs, 810 7th Street Northwest, Washington, DC 20531;
Phone: (202) 353-9254 [Note: this is not a toll-free number]; Email:
phelan.wyric@usdoj.gov.
SUPPLEMENTARY INFORMATION: This meeting is being convened to brief the
OJP Assistant Attorney General and the Board members on the progress of
the subcommittees, discuss any recommendations they may have for
consideration by the full Board, and brief the Board on various OJP-
related projects and activities. The final agenda is subject to
adjustment, but it is anticipated that there will be a morning session
and an afternoon session, with a break for lunch. These sessions will
likely include briefings of the subcommittees' activities and
discussion of future Board actions and priorities.
This meeting is open to the public. Members of the public who wish
to attend this meeting must register with Phelan Wyrick at the above
address at least seven (7) days in advance of the meeting.
Registrations will be accepted on a space available basis. Access to
the meeting will not be allowed without registration. Persons
interested in communicating with the Board should submit their written
comments to the DFO, as the time available will not allow the public to
directly address the Board at the meeting. Anyone requiring special
accommodations should notify Mr. Wyrick at least seven (7) days in
advance of the meeting.
Phelan Wyrick,
Science Policy Advisor and Science Advisory Board DFO, Office of the
Assistant Attorney General, Office of Justice Programs.
[FR Doc. 2013-22628 Filed 9-16-13; 8:45 am]
BILLING CODE 4410-18-P
